INmune Bio(US:INMB)2025-10-30 20:15Financial Performance - Net loss attributable to common stockholders for Q3 2025 was approximately $6.5 million, a decrease from approximately $12.1 million in Q3 2024, representing a 46% improvement[13] - Revenue for the nine months ended September 30, 2025, was $50,000, compared to $14,000 for the same period in 2024, representing a significant increase[23] - Net loss for the nine months ended September 30, 2025, was $40,669, compared to a net loss of $32,864 for the same period in 2024, reflecting a 23.7% increase in losses[23] - The company reported a comprehensive loss of $40,858 for the nine months ended September 30, 2025, compared to $33,101 in 2024, marking a 23.5% increase[23] Expenses - Research and development expenses for Q3 2025 totaled approximately $4.9 million, down from approximately $10.1 million in Q3 2024, indicating a 52% reduction[13] - General and administrative expenses for Q3 2025 were approximately $2.5 million, slightly up from approximately $2.2 million in Q3 2024[13] - Total operating expenses for the nine months ended September 30, 2025, were $41,959, up from $33,182 in 2024, indicating a 26% increase year-over-year[23] - Stock-based compensation for the nine months ended September 30, 2025, was $6,594, compared to $5,848 in 2024, indicating an increase of 12.8%[27] - The company incurred an impairment of acquired in-process research and development intangible assets amounting to $16,514 for the nine months ended September 30, 2025[27] Cash Position - As of September 30, 2025, the company had cash and cash equivalents of approximately $27.7 million, an increase from $20.9 million as of December 31, 2024[21] - Cash and cash equivalents at the end of the period were $27,734, down from $33,552 at the end of the same period in 2024[27] - Net cash used in operating activities for the nine months ended September 30, 2025, was $19,638, compared to $22,348 in 2024, showing a decrease in cash outflow[27] - The net proceeds from the sale of common stock and warrants for the nine months ended September 30, 2025, were $27,544, slightly down from $27,789 in 2024[27] Shareholder Information - The company had approximately 26.6 million common shares outstanding as of October 30, 2025[13] - The weighted average common shares outstanding for the nine months ended September 30, 2025, was 24,141,613, compared to 19,176,853 in 2024, reflecting a 25.9% increase[23] Clinical Developments - The company is on track to file a Marketing Authorization Application (MAA) for CORDStrom™ in mid-2026, followed by a Biologics License Application (BLA) with the FDA[6] - XPro™ demonstrated a consistent clinical benefit in a predefined population of amyloid-positive early Alzheimer's patients, with an effect size of 0.27 for cognitive decline[6] - The CARE-PC trial met its primary endpoint and 2 of 3 secondary endpoints, showing evidence of NK cell proliferation in vivo in 4 of 6 patients at lower dose levels[6] - The company plans to request an End of Phase 2 meeting with the FDA in Q1 2026[6] - Final data analysis for the INKmune CARE-PC trial is expected to be released in Q4 2026[6]